预约演示
更新于：2026-03-18
Infigratinib Phosphate
英菲格拉替尼
更新于：2026-03-18
概要
基本信息
药物类型 小分子化药 |
别名 Infigratinib、BBP-831、BGJ-398 + [7] |
作用方式 拮抗剂 |
作用机制 FGFR1拮抗剂(成纤维细胞生长因子受体-1拮抗剂)、FGFR2拮抗剂(成纤维细胞生长因子受体-2拮抗剂)、FGFR3拮抗剂(成纤维细胞生长因子受体-3拮抗剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-05-28), |
最高研发阶段(中国)临床申请批准 |
特殊审评突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、罕见儿科疾病 (美国)、孤儿药 (欧盟)、突破性疗法 (中国)、孤儿药 (澳大利亚)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C26H34Cl2N7O7P |
InChIKeyGUQNHCGYHLSITB-UHFFFAOYSA-N |
CAS号1310746-10-1 |
关联
34
项与 英菲格拉替尼 相关的临床试验NCT07393373
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Hypochondroplasia: ACCEL OLE
NCT07169279
Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia
NCT06873035
A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children With Hypochondroplasia: ACCEL 2/3
100 项与 英菲格拉替尼 相关的临床结果
登录后查看更多信息
100 项与 英菲格拉替尼 相关的转化医学
登录后查看更多信息
100 项与 英菲格拉替尼 相关的专利（医药）
登录后查看更多信息
311
项与 英菲格拉替尼 相关的文献（医药）2026-05-01CANCER LETTERS
Targeting FGFR1-regulated SPP1 signaling repolarizes immunosuppressive macrophages and sensitizes Hepatocellular Carcinoma to anti-PD-1 therapy
Article
作者: Fu, Jing ; Meng, Zhengyuan ; Gu, Mingye ; Jiang, Youhai ; Wang, Hongyang ; Zong, Yali ; Liu, Xiru ; Chen, Lei ; Liu, Erdong ; Liu, Chunliang ; Li, Jingfeng ; Wang, Xiang ; Chen, Jianan
The response rate to immune checkpoint blockade (ICB) in hepatocellular carcinoma (HCC) remains unsatisfactory, and the mechanisms of resistance are not fully understood. Here, we investigated the role of fibroblast growth factor receptor 1 (FGFR1) in shaping the tumor microenvironment (TME) and mediating ICB resistance. An anti-PD-1-resistant HCC model was established in mice, followed by single-cell RNA sequencing to profile TME alterations. We observed that ICB resistance was associated with FGFR1 upregulation, which activated MAPK signaling and induced SPP1 expression. This cascade promotes macrophage infiltration and M2-type polarization, while simultaneously suppressing T cell recruitment and cytotoxic function, thereby fostering an immunosuppressive microenvironment. SPP1 knockdown or neutralization significantly reduced macrophage accumulation and restored intratumoral T cell infiltration. Importantly, pharmacological inhibition of FGFR1 using BGJ398 synergized with anti-PD-1 therapy, resulting in enhanced antitumor efficacy in preclinical models. Analysis of clinical datasets further revealed that high FGFR1 expression correlated with poor responses to ICB of HCC patients. Collectively, these findings identify FGFR1 as a key mediator of ICB resistance in HCC. Targeting FGFR1 represents a promising strategy to reprogram the immunosuppressive TME and enhance response to immunotherapy, with potential additional value as a predictive biomarker.
2026-02-01JBMR Plus
Inhibition of FGFR signaling with infigratinib improves linear bone growth in the female
Aga2/+
mouse model of osteogenesis imperfecta
Article
作者: Chun, Cora ; Rios, Alma ; Krejci, Pavel ; Bober, Benjamin ; Kot, Alexander ; Bagheri, Roya ; Wachtell, Davis ; Krakow, Deborah ; Wight, Caroline ; Zieba, Jennifer
Abstract:
Osteogenesis imperfecta, a genetically heterogeneous disorder, is characterized by brittle bones with recurrent fractures as well as short stature. A recent study investigating cellular signaling in growth plate chondrocytes identified an increased expression of FGF receptors and elevated FGF signaling. We inhibited FGF receptor activation with the small molecule infigratinib in growing Aga2/+ mice and then characterized linear growth, cartilage growth plate histology, and bone morphometrics. Infigratinib treatment resulted in increased female femur length, increased growth plate lengths in both sexes, specifically in the proliferative zone, and reduced phospho-ERK1/2 as well as SOX9 expression in lower hypertrophic chondrocytes. Infigratinib had no impact on cortical bone but reduced male trabecular bone parameters in Aga2/+ mice. Three point bending biomechanical tests showed that Aga2/+-treated males had increased bone strength for some parameters, but reduced bone strength in treated WT males, correlating with the negative impact on trabecular bone parameters. WT and Aga2-treated male mice also showed increased serum testosterone levels. Together, these data establish FGFR as a therapeutic target for short stature in osteogenesis imperfecta and identify potential negative effects of pan-FGFR inhibition, particularly in the male skeleton.
2026-01-01ARCHIVES OF DISEASE IN CHILDHOOD
Sleep-disordered breathing in children with achondroplasia assessed by polysomnography: a retrospective chart review
Article
作者: Adams, Anne-Marie ; Buchwald, Christian von ; Vandeleur, Moya ; Jacobsen, Jeppe Ravn ; Savarirayan, Ravi ; Buciek, Louise Hove ; Raj, Supriya ; Kiaer, Eva Kirkegaard ; Hove, Hanne B ; Griffiths, Amanda
Objectives:
Sleep-disordered breathing is a key childhood complication in children with achondroplasia. This retrospective study aimed to document the prevalence of sleep-disordered breathing in children with achondroplasia assessed by polysomnography.
Design:
The prevalence of sleep-disordered breathing assessed by polysomnography among children aged 0–18 years with achondroplasia from 2013 to 2024 at The Royal Children’s Hospital, Australia, was retrospectively reviewed.
Results:
The cohort included 80 children with achondroplasia (54% females, 95% confirmed molecular diagnosis) with an average number of 3.6 polysomnographies collected per child (n=288). A total of 85% (68/80) had sleep-disordered breathing and 21% reported no prior symptoms. Sleep-disordered breathing subtypes included obstructive sleep apnoea in 81% (55/68), central sleep apnoea in 3% (2/68), mixed sleep apnoea in 7% (5/68) and primary snoring in 9% (6/68). Among those with obstructive and mixed sleep apnoea, 58% (35/60) had moderate or severe obstructive sleep apnoea. In 44 children, a corresponding MRI was evaluated for foramen magnum stenosis using the Achondroplasia Foramen Magnum Score. No correlation was found with sleep-disordered breathing severity (Spearman’s coefficient (ρ)=0.03). Among 27 children who received a precision therapy for achondroplasia (vosoritide, n=18, infigratinib, n=8 and recifercept, n=1), the median respiratory disturbance index/hour improved from 2.7 (25th–75th percentile, (0.9–4.8)) to 1.1 (0.3–2.6) after 1 year of treatment compared with baseline.
Conclusions:
Sleep-disordered breathing was present in 85% of 80 children with achondroplasia, with 21% being asymptomatic. Respiratory parameters did not correlate with foramen magnum stenosis severity and improved after 1 year of treatment in those treated with a precision therapy.
100 项与 英菲格拉替尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| FGFR2融合或重排的胆管癌 | 美国 | 2021-05-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胆管癌 | 申请上市 | 瑞士 | 2022-01-30 | |
| 软骨发育不良 | 临床3期 | 美国 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 澳大利亚 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 加拿大 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 法国 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 挪威 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 葡萄牙 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 新加坡 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 西班牙 | - | 2025-04-22 |
| 软骨发育不良 | 临床3期 | 瑞典 | - | 2025-04-22 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 9 | 憲網網簾餘窪衊願蓋鹽(範糧築範窪鑰選憲顧壓) = Toxicities included fatigue, visual changes, hyperphosphatemia and stomatitis. Two patients required dose reductions and four required discontinuation due to toxicity (visual changes - 1, hyperphosphatemia - 1 and fatigue - 2) 鹽築選餘構獵壓蓋糧夢 (衊廠夢鏇繭齋夢築廠窪 ) | 积极 | 2026-03-09 | |||
早期临床1期 | 7 | 顧鏇願廠鹹願鏇顧觸蓋(壓鹽網鹹蓋構膚鹽糧夢) = 蓋艱簾膚鏇觸壓鑰築蓋 獵積齋鑰糧壓繭夢蓋鏇 (製範製網膚醖醖醖鑰選, 窪鹽鬱構顧襯膚膚築襯 ~ 築壓鏇淵選鬱鏇窪壓糧) 更多 | - | 2025-10-24 | |||
临床2期 | 17 | 選窪蓋願淵鹽蓋簾簾廠 = 醖鹹餘膚範鹽鑰製繭蓋 積餘獵憲餘衊窪艱窪繭 (襯網膚憲選簾鬱遞製糧, 膚遞網艱選網鏇餘築衊 ~ 繭顧簾淵積鏇顧構襯顧) 更多 | - | 2025-06-10 | |||
临床2期 | 72 | 鏇衊選窪獵淵壓膚選餘(齋襯構糧遞艱艱餘鹹襯) = 願範壓憲鑰鬱襯構遞蓋 鹽鬱窪夢衊鹽廠鬱糧觸 (願襯糧齋觸艱製廠醖艱, 1.22 ~ 3.79) | 积极 | 2025-02-27 | |||
临床1/2期 | 15 | 簾築鑰齋蓋餘鹽廠壓顧 = 鬱糧鏇遞範鏇醖顧築蓋 膚積願網艱顧淵遞範夢 (膚壓鏇壓製鹹鹹憲遞遞, 範餘遞蓋範繭簾範醖製 ~ 醖鏇憲鑰壓鹹齋醖壓鹹) 更多 | - | 2025-01-01 | |||
临床2期 | FGFR2阳性胃癌 FGFR2 Amplification | 21 | Infigratinib 125 mg | 艱繭醖壓網夢範築衊廠(願鏇網構夢願願積廠淵) = 鑰範鏇繭鑰顧窪醖繭廠 夢夢觸鹽餘淵選範醖廠 (膚繭觸獵餘糧鏇鏇網遞 ) 更多 | 积极 | 2024-12-01 | |
临床2期 | 72 | 餘壓鏇遞鏇構艱顧鑰遞(窪繭膚觸繭鹽網願簾廠) = 選積鬱積獵範網鑰觸糧 廠範顧願遞膚繭鏇衊糧 (製遞齋糧醖網鑰夢遞廠, 1.22 ~ 3.79) 更多 | 积极 | 2024-11-18 | |||
临床2期 | 72 | 簾築壓壓構鑰糧窪夢夢(淵鏇繭壓築鹹積鹹簾繭) = 憲醖窪願願膚壓製糧艱 製憲夢壓廠醖蓋繭鬱夢 (鬱鏇願鑰繭餘繭壓選蓋 ) 更多 | 积极 | 2024-11-16 | |||
临床2期 | - | (Cohort 5) | 獵淵網築艱衊構築鬱衊(鑰範壓夢繭齋餘鬱顧範) = 簾醖壓築醖淵觸醖觸夢 窪鑰鑰繭簾窪顧願鬱窪 (襯醖鏇範鬱獵艱鑰顧醖 ) 更多 | 积极 | 2024-06-11 | ||
临床3期 | 39 | (Infigratinib 125 mg) | 夢窪糧廠膚遞鏇糧襯鏇(範鬱觸壓鑰廠餘糧鹹鹽) = 鬱膚糧蓋夢糧蓋衊顧範 選衊觸遞蓋壓鏇糧齋襯 (廠窪夢鏇蓋獵憲糧鏇膚, 簾遞鬱鑰鬱憲遞鹹築廠 ~ 製簾窪糧廠壓壓蓋齋鹹) 更多 | - | 2024-03-13 | ||
Placebo (Placebo) | 夢窪糧廠膚遞鏇糧襯鏇(範鬱觸壓鑰廠餘糧鹹鹽) = 餘鬱繭衊蓋膚艱願製遞 選衊觸遞蓋壓鏇糧齋襯 (廠窪夢鏇蓋獵憲糧鏇膚, 壓壓淵製夢餘網淵鹽糧 ~ 膚艱夢廠鹽構衊鏇鑰憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用